Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Calithera Biosciences, Inc. (CALA)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
343 Oyster Point Boulevard 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Stephanie Wong
Website
calithera.com
IPO
2014-10-02
CIK 1496671 ISIN US13089P5070
Description
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
446
Beta
-1.29
Float Shares
4.83M
Free Float %
99.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +100.00% | -33.33% | +0.00% | -80.00% | +100.00% | +100.00% | -99.23% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (10 ratings, all time)
Buy
Price Targets & DCF
Current price
0.00
Low
2.00
+1,999,900.0%
Consensus
2.00
+1,999,900.0%
Median
2.00
+1,999,900.0%
High
2.00
+1,999,900.0%
DCF (Unlevered)
4.62
+4,622,916.9%
DCF (Levered)
4.76
+4,764,523.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
80% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
2.00
+1,999,900.0%
|
Quality scores
Altman Z-Score
-28.81
Distress
Piotroski F-Score
0 / 9
Weak
MOAT Score
0 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%+74.5% ★ Q4'22: +95.6% (vs Q4'21)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q4'22: +866.0% (vs Q4'21)
-
Share dilution Biotechnology: -3.4%+35.2% Q4'22: +29.8% (vs Q4'21)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.04× Q4'22: -0.06× (vs Q4'21)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
25.96M
est: 25.99M (-0.1%)
|
22.25M
est: 23.96M (-7.1%)
|
—
est: 2.50M (-100.0%)
|
—
est: 480.0K (-100.0%)
|
9.75M
est: 9.78M (-0.3%)
|
—
|
5.00M
est.
|
—
est.
|
62.00M
est.
|
127.36M
127.36M – 127.36M
+105.4% YoY
|
| EBITDA |
-29.69M
est: 5.20M (-671.2%)
|
-57.28M
est: 4.79M (-1,295.2%)
|
-88.02M
est: 500.0K (-17,703.0%)
|
-88.27M
est: 96.0K (-92,045.7%)
|
-113.65M
est: 1.95M (-5,913.5%)
|
-38.27M
|
1,000.0K
est.
|
—
est.
|
12.40M
est.
|
25.47M
25.47M – 25.47M
+105.4% YoY
|
| EBIT |
-29.69M
est: 5.20M (-671.2%)
|
-57.28M
est: 4.79M (-1,295.2%)
|
-89.86M
est: 500.0K (-18,072.0%)
|
-90.14M
est: 96.0K (-93,993.7%)
|
-115.09M
est: 1.95M (-5,986.9%)
|
-39.65M
|
1,000.0K
est.
|
—
est.
|
12.40M
est.
|
25.47M
25.47M – 25.47M
+105.4% YoY
|
| Net Income |
-27.83M
est: -74.72M (+62.8%)
|
-51.47M
est: -146.02M (+64.8%)
|
-86.35M
est: -187.34M (+53.9%)
|
-88.52M
est: -130.38M (+32.1%)
|
-115.09M
est: -86.61M (-32.9%)
|
-18.87M
est: -43.03M (+56.2%)
|
-24.96M
est.
|
-6.59M
est.
|
-10.53M
est.
|
-3.84M
-3.84M – -3.84M
+63.5% YoY
|
| SGA |
12.53M
est: 29.82M (-58.0%)
|
13.34M
est: 27.50M (-51.5%)
|
16.61M
est: 2.87M (+478.8%)
|
20.37M
est: 550.9K (+3,598.2%)
|
20.85M
est: 11.22M (+85.9%)
|
12.16M
|
5.74M
est.
|
—
est.
|
71.15M
est.
|
146.16M
146.16M – 146.16M
+105.4% YoY
|
| EPS |
-16.89
est: -14.97 (-12.8%)
|
-28.12
est: -29.25 (+3.9%)
|
-36.50
est: -37.53 (+2.7%)
|
-26.20
est: -26.12 (-0.3%)
|
-31.16
est: -17.35 (-79.6%)
|
-7.94
est: -8.62 (+7.9%)
|
-5.00
est.
|
-1.32
est.
|
-2.11
est.
|
-0.77
-0.77 – -0.77
+63.5% YoY
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-48.92M
OE per share TTM
-10.53
Owner's Yield
-5,024,349.54%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
40.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
15
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Millennium Pharmaceuticals, Inc. | 14.82M | 13.20% | — | 14.82M | — | 10.00 | CO | Delaware | 2022-04-21 | ↗ |
| 2 | Takeda Pharmaceutical Company Limited | 14.82M | 13.20% | — | 14.82M | — | 10.00 | CO | Japan | 2022-04-21 | ↗ |
| 3 | PRIMECAP Management Company | 10.73M | 14.32% | 10.73M | — | 10.73M | — | IA | 177 E. Colorado Blvd., 11th Floor, Pasadena, CA 91105 | 2022-02-10 | ↗ |
| 4 | (1) BlackRock, Inc. | 2.80M | 3.80% | 2.69M | — | 2.80M | — | HC | Delaware | 2021-07-12 | ↗ |
| 5 | Federated Hermes, Inc. | 1.4K | 0.00% | 1.4K | — | 1.4K | — | HC | Citizenship or place of Organization | 2021-12-10 | ↗ |
| 6 | J. Christopher Donahue | 1.4K | 0.00% | — | 1.4K | — | 1.4K | IN | Citizenship or place of Organization | 2021-12-10 | ↗ |
| 7 | Rhodora J. Donahue | 1.4K | 0.00% | — | 1.4K | — | 1.4K | IN | Citizenship or place of Organization | 2021-12-10 | ↗ |
| 8 | Thomas R. Donahue | 1.4K | 0.00% | — | 1.4K | — | 1.4K | IN | Citizenship or place of Organization | 2021-12-10 | ↗ |
| 9 | Voting Shares Irrevocable Trust | 1.4K | 0.00% | 1.4K | — | 1.4K | — | OO | Citizenship or place of Organization | 2021-12-10 | ↗ |
| 10 | 2. | 10.00 | 5.30% | — | 4.99M | — | — | HC, OO | Delaware | 2022-04-11 | ↗ |
| 11 | Adage Capital Advisors, L.L.C. | — | 0.00% | — | — | — | — | OO | Delaware | 2022-02-10 | ↗ |
| 12 | Adage Capital Partners GP, L.L.C. | — | 0.00% | — | — | — | — | OO | Delaware | 2022-02-10 | ↗ |
| 13 | Adage Capital Partners, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2022-02-10 | ↗ |
| 14 | Phillip Gross | — | 0.00% | — | — | — | — | IN | United States | 2022-02-10 | ↗ |
| 15 | Robert Atchinson | — | 0.00% | — | — | — | — | IN | United States | 2022-02-10 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
6
Shares acquired
—
Shares disposed
2.6K
Cash buys
—
Cash sales
1.00
Net activity
-2,590
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-04-17 | TAKEDA PHARMACEUTICAL CO LTD | — | J-Other | D | Series A Convertible Preferred Stock | 1,000,000 | 40.08 | 40.08M | 0 | — | ↗ |
| 2023-01-27 | PAKIANATHAN DEEPIKA | Director | S-Sale | D | Common Stock | 1,172 | 0.39 | 452.16 | 0 | — | ↗ |
| 2023-01-23 | Wong Stephanie | Officer | F-InKind | D | Common Stock | 317 | 0.45 | 141.41 | 6,287 | — | ↗ |
| 2023-01-23 | Sjogren Eric | Officer | F-InKind | D | Common Stock | 279 | 0.45 | 124.46 | 8,467 | — | ↗ |
| 2023-01-23 | Molineaux Susan | Officer | F-InKind | D | Common Stock | 526 | 0.45 | 234.65 | 27,859 | — | ↗ |
| 2023-01-23 | Molineaux Christopher | Officer | F-InKind | D | Common Stock | 217 | 0.45 | 96.80 | 27,859 | — | ↗ |
| 2023-01-23 | Kuriakose Emil | Officer | F-InKind | D | Common Stock | 79 | 0.45 | 35.24 | 3,539 | — | ↗ |
| 2022-07-01 | Takeda Ventures, Inc. | Director | J-Other | D | Series A Convertible Preferred Stock | 1,000,000 | 0.00 | — | 0 | — | ↗ |
| 2022-07-01 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | J-Other | D | Series A Convertible Preferred Stock | 1,000,000 | 40.08 | 40.08M | 0 | — | ↗ |
| 2022-06-01 | Wolff Henry Ward | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-01 | Wise Blake | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-01 | PAKIANATHAN DEEPIKA | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.20 | 4.0K | 20,000 | — | ↗ |
| 2022-06-01 | Orford Keith | Director | A-Award | A | Employee Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-01 | JONES SUZY | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-01 | Garland J. Scott | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-01 | AGARWAL SUNIL | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-01-25 | Wong Stephanie | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 215,000 | 0.44 | 94.6K | 215,000 | — | ↗ |
| 2022-01-25 | Sjogren Eric | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 165,000 | 0.44 | 72.6K | 165,000 | — | ↗ |
| 2022-01-25 | Ray Sumita | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 165,000 | 0.44 | 72.6K | 165,000 | — | ↗ |
| 2022-01-25 | Parlati Francesco | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 165,000 | 0.44 | 72.6K | 165,000 | — | ↗ |
| 2022-01-25 | Orford Keith | Director | A-Award | A | Employee Stock Option (Right to Buy) | 40,000 | 0.44 | 17.6K | 40,000 | — | ↗ |
| 2022-01-25 | Molineaux Susan | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 597,475 | 0.44 | 262.9K | 597,475 | — | ↗ |
| 2022-01-25 | Molineaux Christopher | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 165,000 | 0.44 | 72.6K | 165,000 | — | ↗ |
| 2022-01-25 | Kuriakose Emil | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 215,000 | 0.44 | 94.6K | 215,000 | — | ↗ |
| 2022-01-21 | Wong Stephanie | Officer | F-InKind | D | Common Stock | 5,586 | 0.49 | 2.7K | 132,085 | — | ↗ |
| 2022-01-21 | Sjogren Eric | Officer | F-InKind | D | Common Stock | 4,794 | 0.49 | 2.4K | 172,434 | — | ↗ |
| 2022-01-21 | Parlati Francesco | Officer | F-InKind | D | Common Stock | 4,794 | 0.49 | 2.4K | 140,998 | — | ↗ |
| 2022-01-21 | Kuriakose Emil | Officer | F-InKind | D | Common Stock | 666 | 0.49 | 327.34 | 67,369 | — | ↗ |
| 2022-01-04 | Wong Stephanie | Officer | F-InKind | D | Common Stock | 18,077 | 0.66 | 11.9K | 137,671 | — | ↗ |
| 2022-01-04 | Sjogren Eric | Officer | F-InKind | D | Common Stock | 18,077 | 0.66 | 11.9K | 177,228 | — | ↗ |
| 2022-01-04 | Parlati Francesco | Officer | F-InKind | D | Common Stock | 18,077 | 0.66 | 11.9K | 145,792 | — | ↗ |
| 2022-01-04 | Kuriakose Emil | Officer | F-InKind | D | Common Stock | 3,855 | 0.66 | 2.5K | 68,035 | — | ↗ |
| 2021-11-11 | Orford Keith | Director / Officer | S-Sale | D | Common Stock | 48,190 | 0.88 | 42.4K | 66,094 | — | ↗ |
| 2021-11-10 | Orford Keith | Director / Officer | S-Sale | D | Common Stock | 30,000 | 0.86 | 25.7K | 114,284 | — | ↗ |
| 2021-11-10 | Molineaux Susan | Director / Officer | P-Purchase | A | Common Stock | 100,000 | 0.85 | 84.7K | 557,188 | — | ↗ |
| 2021-11-10 | Molineaux Christopher | Officer | P-Purchase | A | Common Stock | 100,000 | 0.85 | 84.7K | 557,188 | — | ↗ |
| 2021-11-10 | DRACHMAN JONATHAN G | Director | P-Purchase | A | Common Stock | 200,000 | 0.86 | 171.9K | 200,000 | — | ↗ |
| 2021-11-09 | Orford Keith | Director | S-Sale | D | Common Stock | 51,810 | 0.84 | 43.5K | 144,284 | — | ↗ |
| 2021-11-08 | Wong Stephanie | Officer | F-InKind | D | Common Stock | 15,566 | 0.87 | 13.5K | 155,748 | — | ↗ |
| 2021-11-08 | Sjogren Eric | Officer | F-InKind | D | Common Stock | 15,566 | 0.87 | 13.5K | 195,305 | — | ↗ |
| 2021-11-08 | Parlati Francesco | Officer | F-InKind | D | Common Stock | 15,566 | 0.87 | 13.5K | 163,869 | — | ↗ |
| 2021-11-08 | Kuriakose Emil | Officer | F-InKind | D | Common Stock | 3,077 | 0.87 | 2.7K | 69,390 | — | ↗ |
| 2021-11-05 | Wong Stephanie | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 171,314 | — | ↗ |
| 2021-11-05 | Sjogren Eric | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 210,871 | — | ↗ |
| 2021-11-05 | Ray Sumita | Officer | A-Award | A | Common Stock | 12,000 | 0.00 | — | 105,000 | — | ↗ |
| 2021-11-05 | Parlati Francesco | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 179,435 | — | ↗ |
| 2021-11-05 | Orford Keith | Director | A-Award | A | Common Stock | 30,000 | 0.00 | — | 196,094 | — | ↗ |
| 2021-11-05 | Molineaux Christopher | Officer | A-Award | A | Common Stock | 12,000 | 0.00 | — | 102,500 | — | ↗ |
| 2021-11-05 | Kuriakose Emil | Officer | — | D | STOCK OPTION (RIGHT TO BUY) | 12,667 | 5.61 | 71.1K | 0 | — | ↗ |
| 2021-10-28 | Wong Stephanie | Officer | F-InKind | D | Common Stock | 45,965 | 1.89 | 86.9K | 141,314 | — | ↗ |
| 2021-10-28 | Sjogren Eric | Officer | F-InKind | D | Common Stock | 45,965 | 1.89 | 86.9K | 180,871 | — | ↗ |
| 2021-10-28 | Parlati Francesco | Officer | F-InKind | D | Common Stock | 45,965 | 1.89 | 86.9K | 149,435 | — | ↗ |
| 2021-10-27 | Wong Stephanie | Officer | A-Award | A | Common Stock | 90,000 | 0.00 | — | 187,279 | — | ↗ |
| 2021-10-27 | Sjogren Eric | Officer | A-Award | A | Common Stock | 90,000 | 0.00 | — | 226,836 | — | ↗ |
| 2021-10-27 | Ray Sumita | Officer | A-Award | A | Common Stock | 36,000 | 0.00 | — | 93,000 | — | ↗ |
| 2021-10-27 | Parlati Francesco | Officer | A-Award | A | Common Stock | 90,000 | 0.00 | — | 195,400 | — | ↗ |
| 2021-10-27 | Orford Keith | Officer | A-Award | A | Common Stock | 90,000 | 0.00 | — | 166,094 | — | ↗ |
| 2021-10-27 | Molineaux Christopher | Officer | A-Award | A | Common Stock | 36,000 | 0.00 | — | 90,500 | — | ↗ |
| 2021-10-18 | TAKEDA PHARMACEUTICAL CO LTD | 10% Owner | — | I | Series A Convertible Preferred Stock | 1,000,000 | 2.04 | 2.04M | 0 | — | ↗ |
| 2021-06-11 | Wolff Henry Ward | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 2.28 | 45.6K | 20,000 | — | ↗ |
| 2021-06-11 | Wise Blake | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 2.28 | 45.6K | 20,000 | — | ↗ |
| 2021-06-11 | PAKIANATHAN DEEPIKA | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 2.28 | 45.6K | 20,000 | — | ↗ |
| 2021-06-11 | JONES SUZY | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 2.28 | 45.6K | 20,000 | — | ↗ |
| 2021-06-11 | George Jean | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 2.28 | 45.6K | 20,000 | — | ↗ |
| 2021-06-11 | Garland J. Scott | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 2.28 | 45.6K | 20,000 | — | ↗ |
| 2021-06-11 | DRACHMAN JONATHAN G | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 2.28 | 45.6K | 20,000 | — | ↗ |
| 2021-06-11 | AGARWAL SUNIL | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 2.28 | 45.6K | 20,000 | — | ↗ |
| 2021-01-20 | Wong Stephanie | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 150,000 | 2.98 | 447.0K | 150,000 | — | ↗ |
| 2021-01-20 | Sjogren Eric | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 125,000 | 2.98 | 372.5K | 125,000 | — | ↗ |
| 2021-01-20 | Ray Sumita | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 45,000 | — | ↗ |
| 2021-01-20 | Parlati Francesco | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 125,000 | 2.98 | 372.5K | 125,000 | — | ↗ |
| 2021-01-20 | Orford Keith | Officer | A-Award | A | Common Stock | 35,000 | 0.00 | — | 46,094 | — | ↗ |
| 2021-01-20 | Molineaux Susan | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 375,000 | 2.98 | 1.12M | 375,000 | — | ↗ |
| 2021-01-20 | Molineaux Christopher | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 40,000 | — | ↗ |
| 2021-01-20 | Hecht Curtis | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 150,000 | 2.98 | 447.0K | 150,000 | — | ↗ |
| 2020-12-16 | Orford Keith | Officer | S-Sale | D | Common Stock | 2,447 | 6.00 | 14.7K | 11,094 | — | ↗ |
| 2020-07-31 | Garland J. Scott | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 4.70 | 188.0K | 40,000 | — | ↗ |
| 2020-07-10 | Garland J. Scott | Director | — | D | No securities beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-09 | Wolff Henry Ward | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 5.25 | 105.0K | 20,000 | — | ↗ |
| 2020-06-09 | Wise Blake | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 5.25 | 105.0K | 20,000 | — | ↗ |
| 2020-06-09 | PAKIANATHAN DEEPIKA | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 5.25 | 105.0K | 20,000 | — | ↗ |
| 2020-06-09 | JONES SUZY | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 5.25 | 105.0K | 20,000 | — | ↗ |
| 2020-06-09 | George Jean | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 5.25 | 105.0K | 20,000 | — | ↗ |
| 2020-06-09 | DRACHMAN JONATHAN G | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 5.25 | 105.0K | 20,000 | — | ↗ |
| 2020-06-09 | AGARWAL SUNIL | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 5.25 | 105.0K | 20,000 | — | ↗ |
| 2020-05-21 | BVF PARTNERS L P/IL | 10% Owner | S-Sale | D | Common Stock, $0.0001 par value | 1,027,016 | 6.00 | 6.16M | 3,712,340 | — | ↗ |
| 2020-04-15 | Wong Stephanie | Officer | S-Sale | D | Common Stock | 5,000 | 8.00 | 40.0K | 30,082 | — | ↗ |
| 2020-02-20 | Orford Keith | Officer | S-Sale | D | Common Stock | 3,021 | 8.00 | 24.2K | 8,541 | — | ↗ |
| 2020-01-18 | Molineaux Susan | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 400,000 | 7.41 | 2.96M | 400,000 | — | ↗ |
| 2020-01-17 | Wong Stephanie | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 120,000 | 7.41 | 889.2K | 120,000 | — | ↗ |
| 2020-01-17 | Sjogren Eric | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 110,000 | 7.41 | 815.1K | 110,000 | — | ↗ |
| 2020-01-17 | Ray Sumita | Officer | A-Award | A | Stock Option (Right to Buy) | 110,000 | 7.41 | 815.1K | 110,000 | — | ↗ |
| 2020-01-17 | Parlati Francesco | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 75,000 | 7.41 | 555.8K | 75,000 | — | ↗ |
| 2020-01-17 | Orford Keith | Officer | A-Award | A | Stock Option (Right to Buy) | 140,000 | 7.41 | 1.04M | 140,000 | — | ↗ |
| 2020-01-17 | Molineaux Christopher | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 110,000 | 7.41 | 815.1K | 110,000 | — | ↗ |
| 2020-01-17 | Hecht Curtis | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 120,000 | 7.41 | 889.2K | 120,000 | — | ↗ |
| 2019-12-23 | Orford Keith | Officer | S-Sale | D | Common Stock | 3,021 | 6.00 | 18.1K | 11,562 | — | ↗ |
| 2019-11-20 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value | 79,285 | 3.91 | 310.1K | 3,830,893 | — | ↗ |
| 2019-11-14 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value | 45,888 | 3.37 | 154.6K | 3,751,608 | — | ↗ |
| 2019-10-30 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value | 408,592 | 2.70 | 1.10M | 4,569,343 | — | ↗ |
| 2019-10-29 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.0001 par value | 872,373 | 2.60 | 2.27M | 4,160,751 | — | ↗ |
| 2019-06-25 | Molineaux Susan | Director / Officer | P-Purchase | A | Common Stock | 51,600 | 3.88 | 200.2K | 457,188 | — | ↗ |
| 2019-06-25 | Molineaux Christopher | Officer | P-Purchase | A | Common Stock | 51,600 | 3.88 | 200.2K | 457,188 | — | ↗ |
| 2019-06-24 | Sjogren Eric | Officer | M-Exempt | A | Common Stock | 21,739 | 0.96 | 20.9K | 72,057 | — | ↗ |
| 2019-06-19 | Wong Stephanie | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 10,000 | 2.64 | 26.4K | 13,284 | — | ↗ |
| 2019-06-19 | BVF PARTNERS L P/IL | 10% Owner | — | D | Common Stock, $0.0001 par value | 0 | 0.00 | — | 473,006 | — | ↗ |
| 2019-06-17 | Parlati Francesco | Officer | M-Exempt | A | Common Stock | 6,246 | 2.64 | 16.5K | 42,201 | — | ↗ |
| 2019-06-17 | Orford Keith | Officer | S-Sale | D | Common Stock | 417 | 6.00 | 2.5K | 12,083 | — | ↗ |
| 2019-05-30 | Wolff Henry Ward | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 5.42 | 59.6K | 11,000 | — | ↗ |
| 2019-05-30 | Wise Blake | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 5.42 | 59.6K | 11,000 | — | ↗ |
| 2019-05-30 | PAKIANATHAN DEEPIKA | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 5.42 | 59.6K | 11,000 | — | ↗ |
| 2019-05-30 | JONES SUZY | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 5.42 | 59.6K | 11,000 | — | ↗ |
| 2019-05-30 | George Jean | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 5.42 | 59.6K | 11,000 | — | ↗ |
| 2019-05-30 | DRACHMAN JONATHAN G | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 5.42 | 59.6K | 11,000 | — | ↗ |
| 2019-05-30 | AGARWAL SUNIL | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 5.42 | 59.6K | 11,000 | — | ↗ |
| 2019-05-22 | Orford Keith | Officer | S-Sale | D | Common Stock | 416 | 6.00 | 2.5K | 10,000 | — | ↗ |
| 2019-04-15 | Orford Keith | Officer | S-Sale | D | Common Stock | 416 | 6.33 | 2.6K | 10,416 | — | ↗ |
| 2019-03-15 | Orford Keith | Officer | S-Sale | D | Common Stock | 417 | 6.43 | 2.7K | 10,832 | — | ↗ |
| 2019-03-11 | Orford Keith | Officer | S-Sale | D | Common Stock | 1,565 | 6.00 | 9.4K | 11,249 | — | ↗ |
| 2019-02-07 | Molineaux Susan | Director / Officer | G-Gift | D | Common Stock | 12,986 | 0.00 | — | 395,588 | — | ↗ |
| 2019-02-07 | Molineaux Christopher | Officer | G-Gift | D | Common Stock | 12,986 | 0.00 | — | 395,588 | — | ↗ |
| 2019-01-10 | Wong Stephanie | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 120,000 | 4.64 | 556.8K | 120,000 | — | ↗ |
| 2019-01-10 | Sjogren Eric | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 100,000 | 4.64 | 464.0K | 100,000 | — | ↗ |
| 2019-01-10 | Ray Sumita | Officer | A-Award | A | Stock Option (Right to Buy) | 90,000 | 4.64 | 417.6K | 90,000 | — | ↗ |
| 2019-01-10 | Parlati Francesco | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 47,000 | 4.64 | 218.1K | 47,000 | — | ↗ |
| 2019-01-10 | Orford Keith | Officer | A-Award | A | Stock Option (Right to Buy) | 132,000 | 4.64 | 612.5K | 132,000 | — | ↗ |
| 2019-01-10 | Molineaux Susan | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 390,000 | 4.64 | 1.81M | 390,000 | — | ↗ |
| 2019-01-10 | Molineaux Christopher | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 105,000 | 4.64 | 487.2K | 105,000 | — | ↗ |
| 2019-01-10 | Hecht Curtis | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 117,000 | 4.64 | 542.9K | 117,000 | — | ↗ |
| 2018-11-14 | Molineaux Susan | Director / Officer | G-Gift | D | Common Stock | 6,476 | 0.00 | — | 408,574 | — | ↗ |
| 2018-11-14 | Molineaux Christopher | Officer | G-Gift | D | Common Stock | 6,476 | 0.00 | — | 408,574 | — | ↗ |
| 2018-10-15 | Orford Keith | Officer | S-Sale | D | Common Stock | 313 | 6.05 | 1.9K | 10,314 | — | ↗ |
| 2018-10-11 | Orford Keith | Officer | S-Sale | D | Common Stock | 1,252 | 6.00 | 7.5K | 10,627 | — | ↗ |
| 2018-10-09 | Ray Sumita | Officer | A-Award | A | Stock Option (Right to Buy) | 25,000 | 5.61 | 140.3K | 25,000 | — | ↗ |
| 2018-05-31 | Wolff Henry Ward | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 5.15 | 56.7K | 11,000 | — | ↗ |
| 2018-05-31 | Wise Blake | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 5.15 | 56.7K | 11,000 | — | ↗ |
| 2018-05-31 | PAKIANATHAN DEEPIKA | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 5.15 | 56.7K | 11,000 | — | ↗ |
| 2018-05-31 | JONES SUZY | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 5.15 | 56.7K | 11,000 | — | ↗ |
| 2018-05-31 | George Jean | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 5.15 | 56.7K | 11,000 | — | ↗ |
| 2018-05-31 | DRACHMAN JONATHAN G | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 5.15 | 56.7K | 11,000 | — | ↗ |
| 2018-05-31 | AGARWAL SUNIL | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 5.15 | 56.7K | 11,000 | — | ↗ |
| 2018-04-03 | Sjogren Eric | Officer | M-Exempt | A | Common Stock | 16,810 | 0.48 | 8.1K | 42,818 | — | ↗ |
| 2018-03-02 | Molineaux Susan | Director / Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 26,992 | 2.64 | 71.3K | 9,729 | — | ↗ |
| 2018-03-02 | Molineaux Christopher | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 6,798 | 2.64 | 17.9K | 0 | — | ↗ |
| 2018-02-23 | Wong Stephanie | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 10,000 | 2.64 | 26.4K | 21,596 | — | ↗ |
| 2018-02-20 | Parlati Francesco | Officer | M-Exempt | A | Common Stock | 3,116 | 0.96 | 3.0K | 28,455 | — | ↗ |
| 2018-01-11 | Wong Stephanie | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 70,000 | 8.60 | 602.0K | 70,000 | — | ↗ |
| 2018-01-11 | Sjogren Eric | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 60,000 | 8.60 | 516.0K | 60,000 | — | ↗ |
| 2018-01-11 | Parlati Francesco | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 30,000 | 8.60 | 258.0K | 30,000 | — | ↗ |
| 2018-01-11 | Orford Keith | Officer | A-Award | A | Stock Option (Right to Buy) | 70,000 | 8.60 | 602.0K | 70,000 | — | ↗ |
| 2018-01-11 | Molineaux Susan | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 200,000 | 8.60 | 1.72M | 200,000 | — | ↗ |
| 2018-01-11 | Molineaux Christopher | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 65,000 | 8.60 | 559.0K | 65,000 | — | ↗ |
| 2018-01-11 | Hecht Curtis | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 70,000 | 8.60 | 602.0K | 70,000 | — | ↗ |
| 2017-12-05 | Molineaux Susan | Director / Officer | M-Exempt | A | Common Stock | 5,300 | 2.64 | 14.0K | 15,368 | — | ↗ |
| 2017-12-05 | Molineaux Christopher | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 5,300 | 2.64 | 14.0K | 34,030 | — | ↗ |
| 2017-09-29 | Ray Sumita | Officer | — | D | No securities beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-09-28 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 10% Owner | S-Sale | D | Common Stock | 38,000 | 15.50 | 589.0K | 3,546,873 | — | ↗ |
| 2017-09-27 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 10% Owner | S-Sale | D | Common Stock | 186,000 | 15.59 | 2.90M | 3,584,873 | — | ↗ |
| 2017-09-26 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 10% Owner | S-Sale | D | Common Stock, par value $0.0001 ("Common Stock") | 352,000 | 15.68 | 5.52M | 3,770,873 | — | ↗ |
| 2017-09-20 | Wise Blake | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 15.75 | 346.5K | 22,000 | — | ↗ |
| 2017-07-17 | Wong Stephanie | Officer | S-Sale | D | Common Stock | 3,552 | 18.41 | 65.4K | 10,550 | — | ↗ |
| 2017-07-17 | Orford Keith | Officer | S-Sale | D | Common Stock | 2,120 | 18.31 | 38.8K | 6,879 | — | ↗ |
| 2017-07-06 | Hecht Curtis | Officer | S-Sale | D | Common Stock | 700 | 18.00 | 12.6K | 15,940 | — | ↗ |
| 2017-06-09 | Wolff Henry Ward | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 14.20 | 156.2K | 11,000 | — | ↗ |
| 2017-06-09 | PAKIANATHAN DEEPIKA | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 14.20 | 156.2K | 11,000 | — | ↗ |
| 2017-06-09 | JONES SUZY | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 14.20 | 156.2K | 11,000 | — | ↗ |
| 2017-06-09 | George Jean | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 14.20 | 156.2K | 11,000 | — | ↗ |
| 2017-06-09 | DRACHMAN JONATHAN G | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 14.20 | 156.2K | 11,000 | — | ↗ |
| 2017-06-09 | AGARWAL SUNIL | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 14.20 | 156.2K | 11,000 | — | ↗ |
| 2017-06-01 | MORGENTHALER VENTURE PARTNERS IX LP | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-05-19 | Hecht Curtis | Officer | S-Sale | D | Common Stock | 650 | 16.00 | 10.4K | 14,910 | — | ↗ |
| 2017-03-22 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 10% Owner | P-Purchase | A | Common Stock, par value $0.0001 ("Common Stock") | 487,804 | 10.25 | 5.00M | 4,122,873 | — | ↗ |
| 2017-03-13 | Hecht Curtis | Officer | S-Sale | D | Common Stock | 600 | 14.00 | 8.4K | 15,560 | — | ↗ |
| 2017-03-02 | Hecht Curtis | Officer | S-Sale | D | Common Stock | 550 | 12.00 | 6.6K | 16,160 | — | ↗ |
| 2017-01-01 | Wong Stephanie | Officer | — | D | STOCK OPTION (RIGHT TO BUY) | 33,284 | 2.64 | 87.9K | 0 | — | ↗ |
| 2017-01-01 | Parlati Francesco | Officer | — | D | STOCK OPTION (RIGHT TO BUY) | 7,000 | 16.40 | 114.8K | 0 | — | ↗ |
| 2016-12-19 | Molineaux Susan | Director / Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 5,418 | 0.96 | 5.2K | 6,502 | — | ↗ |
| 2016-12-19 | Molineaux Christopher | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 5,418 | 0.96 | 5.2K | 6,502 | — | ↗ |
| 2016-11-29 | Waddill William D. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 75,000 | 3.35 | 251.3K | 75,000 | — | ↗ |
| 2016-11-29 | Sjogren Eric | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 75,000 | 3.35 | 251.3K | 75,000 | — | ↗ |
| 2016-11-29 | Orford Keith | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 3.35 | 251.3K | 75,000 | — | ↗ |
| 2016-11-29 | Molineaux Susan | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 165,000 | 3.35 | 552.8K | 165,000 | — | ↗ |
| 2016-11-29 | Molineaux Christopher | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 75,000 | 3.35 | 251.3K | 75,000 | — | ↗ |
| 2016-11-29 | Hecht Curtis | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 75,000 | 3.35 | 251.3K | 75,000 | — | ↗ |
| 2016-11-29 | Bennett Mark K | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 56,250 | 3.35 | 188.4K | 56,250 | — | ↗ |
| 2016-11-16 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 10% Owner | P-Purchase | A | Common Stock, par value $0.0001 ("Common Stock") | 500,000 | 3.15 | 1.58M | 3,635,069 | — | ↗ |
| 2016-09-29 | Waddill William D. | Officer | J-Other | D | Common Stock | 17,485 | 0.00 | — | 17,485 | — | ↗ |
| 2016-08-09 | JONES SUZY | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 3.26 | 71.7K | 22,000 | — | ↗ |
| 2016-08-08 | Hecht Curtis | Officer | J-Other | A | Common Stock | 3,085 | 0.00 | — | 14,210 | — | ↗ |
| 2016-07-20 | Molineaux Susan | Director / Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 4,410 | 0.48 | 2.1K | 0 | — | ↗ |
| 2016-07-20 | Molineaux Christopher | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 4,410 | 0.48 | 2.1K | 0 | — | ↗ |
| 2016-06-14 | Wolff Henry Ward | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 4.76 | 52.4K | 11,000 | — | ↗ |
| 2016-06-14 | PAKIANATHAN DEEPIKA | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 11,000 | 4.76 | 52.4K | 11,000 | — | ↗ |
| 2016-06-14 | George Jean | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 11,000 | 4.76 | 52.4K | 11,000 | — | ↗ |
| 2016-06-14 | DRACHMAN JONATHAN G | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 4.76 | 52.4K | 11,000 | — | ↗ |
| 2016-06-14 | AGARWAL SUNIL | Director | A-Award | A | Stock Option (Right to Buy) | 11,000 | 4.76 | 52.4K | 11,000 | — | ↗ |
| 2016-05-02 | Orford Keith | Officer | — | D | STOCK OPTION (RIGHT TO BUY) | 55,000 | 19.89 | 1.09M | 0 | — | ↗ |
| 2016-01-19 | Waddill William D. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 70,000 | 4.71 | 329.7K | 70,000 | — | ↗ |
| 2016-01-19 | Sjogren Eric | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 70,000 | 4.71 | 329.7K | 70,000 | — | ↗ |
| 2016-01-19 | Molineaux Susan | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 185,000 | 4.71 | 871.4K | 185,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
4.87M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2021 | Susan Molineaux, Ph.D. President and Chief Executive Officer | 589.2K | 318.2K | 253.3K | 812.5K | — | 15.8K | 1.99M | 53.58% | ↗ |
| 2 | 2021 | Stephanie Wong Chief Financial Officer & Secretary | 413.7K | 177.2K | 551.3K | 325.0K | — | 25.5K | 1.49M | 58.71% | ↗ |
| 3 | 2021 | Eric Sjogren, Ph.D. Senior Vice President, Drug Discovery | 400.5K | 147.4K | 536.4K | 270.8K | — | 31.2K | 1.39M | 58.23% | ↗ |
| 4 | 2021 | Keith Orford, M.D., Ph.D. Former Chief Medical Officer | 416.1K | 56.6K | 551.3K | 325.0K | — | 23.6K | 1.37M | 63.84% | ↗ |
| 5 | 2020 | Susan Molineaux, Ph.D. President and Chief Executive Officer | 569.3K | 222.0K | — | 2.81M | — | 15.7K | 3.62M | 77.71% | ↗ |
| 6 | 2020 | Keith Orford, M.D., Ph.D. Chief Medical Officer | 455.4K | 149.4K | — | 772.4K | — | 24.3K | 1.40M | 55.11% | ↗ |
| 7 | 2020 | Keith Orford, M.D., Ph.D. Former Chief Medical Officer | 455.4K | 149.4K | — | 772.4K | — | 24.3K | 1.40M | 55.11% | ↗ |
| 8 | 2020 | Curtis C. Hecht Former Chief Business Officer | 400.1K | 131.2K | — | 662.0K | — | 9.3K | 1.20M | 55.05% | ↗ |
| 9 | 2019 | Susan Molineaux, Ph.D. President and Chief Executive Officer | 550.0K | 321.8K | — | 1.32M | — | 15.3K | 2.21M | 59.86% | ↗ |
| 10 | 2019 | Keith Orford, M.D., Ph.D. Chief Medical Officer | 440.0K | 172.5K | — | 447.7K | — | 181.4K | 1.24M | 36.06% | ↗ |
| 11 | 2019 | Curtis C. Hecht Chief Business Officer | 380.0K | 149.0K | — | 396.8K | — | 9.2K | 935.0K | 42.44% | ↗ |
| 12 | 2019 | Curtis C. Hecht Former Chief Business Officer | 380.0K | 149.0K | — | 396.8K | — | 9.2K | 935.0K | 42.44% | ↗ |
| 13 | 2018 | Susan Molineaux, Ph.D. President and Chief Executive Officer | 530.0K | 254.4K | — | 1.24M | — | 5.6K | 2.03M | 61.15% | ↗ |
| 14 | 2018 | Keith Orford, M.D., Ph.D. Chief Medical Officer | 400.0K | 134.4K | — | 435.2K | — | 174.0K | 1.14M | 38.06% | ↗ |
| 15 | 2018 | Curtis C. Hecht Chief Business Officer | 335.0K | 112.6K | — | 435.2K | — | 652.00 | 883.4K | 49.26% | ↗ |
| 16 | 2018 | Curtis Hecht Chief Business Officer | 335.0K | 112.6K | — | 435.2K | — | 652.00 | 883.4K | 49.26% | ↗ |
| 17 | 2017 | Sumita Ray Sr. Vice President, General Counsel and Chief Compliance Officer | 350.0K | — | — | 913.0K | — | 75.00 | 1.26M | 72.28% | ↗ |
| 18 | 2017 | Susan Molineaux, Ph.D. President and Chief Executive Officer | 504.0K | 252.0K | — | — | — | 4.9K | 760.9K | 0.00% | ↗ |
| 19 | 2017 | Keith Orford, M.D., Ph.D. Chief Medical Officer | 350.0K | 154.0K | — | — | — | 144.7K | 648.7K | 0.00% | ↗ |
| 20 | 2017 | Keith Orford, M.D., Ph.D. Sr. Vice President, Clinical Development | 350.0K | 154.0K | — | — | — | 144.7K | 648.7K | 0.00% | ↗ |
| 21 | 2016 | Susan Molineaux, Ph.D. President and Chief Executive Officer | 475.0K | 237.5K | — | 1.01M | — | 4.5K | 1.72M | 58.41% | ↗ |
| 22 | 2016 | William D. Waddill Former Senior Vice President, Chief Finance Officer, Secretary and Treasurer | 345.0K | — | — | 412.8K | — | 386.6K | 1.14M | 36.07% | ↗ |
| 23 | 2016 | Keith Orford, M.D., Ph.D. Sr. Vice President, Clinical Development | 333.7K | 111.4K | — | 414.2K | — | 119.2K | 978.5K | 42.33% | ↗ |
| 24 | 2015 | Susan Molineaux, Ph.D. President and Chief Executive Officer | 440.0K | 176.0K | — | 2.75M | — | 18.1K | 3.38M | 81.24% | ↗ |
| 25 | 2015 | William D. Waddill Senior Vice President, Chief Finance Officer, Secretary and Treasurer | 325.0K | 95.6K | — | 543.4K | — | 1.9K | 965.9K | 56.26% | ↗ |
| 26 | 2015 | William D. Waddill Former Senior Vice President, Chief Finance Officer, Secretary and Treasurer | 325.0K | 95.6K | — | 543.4K | — | 1.9K | 965.9K | 56.26% | ↗ |
| 27 | 2015 | Eric Sjogren, Ph.D. Sr. Vice President, Drug Discovery | 315.0K | 92.6K | — | 543.4K | — | 8.5K | 959.5K | 56.63% | ↗ |
| 28 | 2014 | Susan Molineaux, Ph.D. President and Chief Executive Officer | 400.0K | 160.0K | — | 358.9K | — | 4.1K | 923.0K | 38.88% | ↗ |
| 29 | 2014 | William D. Waddill Senior Vice President, Chief Finance Officer, Secretary and Treasurer | 232.5K | 96.7K | — | 506.4K | — | 1.3K | 837.0K | 60.51% | ↗ |
| 30 | 2014 | Susan Molineaux, Ph D. President and Chief Executive Officer | 400.0K | 160.0K | — | — | — | — | 685.4K | 0.00% | ↗ |
| 31 | 2014 | Eric Sjogren, Ph.D. Sr. Vice President, Drug Discovery | 300.0K | 105.0K | — | 105.6K | — | 2.1K | 512.7K | 20.59% | ↗ |
| 32 | 2014 | Christopher J. Molineaux, Ph.D. | 300.0K | 105.0K | — | — | — | — | 446.6K | 0.00% | ↗ |
| 33 | 2014 | Eric Sjogren, Ph.D. Sr. Vice President, Drug Discovery | 300.0K | 105.0K | — | — | — | — | 445.1K | 0.00% | ↗ |
| 34 | 2013 | Susan Molineaux, Ph D. President and Chief Executive Officer | 350.0K | 134.8K | — | — | — | — | 502.4K | 0.00% | ↗ |
| 35 | 2013 | Eric Sjogren, Ph.D. Sr. Vice President, Drug Discovery | 275.0K | 89.1K | — | — | — | — | 372.5K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Stephanie Wong | Chief Financial Officer & Secretary | 752.4K | female |
| Christopher J. Molineaux | Senior Vice President of Development | 405.0K | — |
| Frank Parlati | Senior Vice President of Research | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CALA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
